Ignite Creation Date:
2024-05-06 @ 2:12 PM
Last Modification Date:
2024-10-26 @ 1:27 PM
Study NCT ID:
NCT04249739
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-13
First Post:
2020-01-21
Brief Title:
Pembrolizumab CapecitabineOxaliplatin CapeOx -HER2 Nagative and Pembrolizumab Trastuzumab CisplatinCapecitabine HER2 Positive
Sponsor:
Samsung Medical Center
Organization:
Samsung Medical Center
Organization Data
Organization:
Samsung Medical Center
Class:
OTHER
Study ID:
2019-11-089
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Samsung Medical Center
Lead Sponsor Class:
OTHER
Responsible Party:
Jeeyun Lee
Responsible Party Title:
MD PhDPrincipal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Samsung Medical Center
Old Name:
None
Old Organization:
None